Impact of molecular profiling on clinical trial design for glioblastoma.
This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy.
Chakravarti
Arnab
A
Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA. achakravarti@partners.org
Tyndall
Erin
E
Palanichamy
Kamalakannan
K
Mehta
Minesh
M
Aldape
Kenneth
K
Loeffler
Jay
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D002986:Clinical Trials as Topic; D020869:Gene Expression Profiling; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D012107:Research Design; D015398:Signal Transduction / Q000187:drug effects*
D000970:Antineoplastic Agents